Skip Navigation LinksHome > April 2012 - Volume 31 - Issue 4 > Effects of Topical Human Amniotic Fluid and Human Serum in a...
Cornea:
doi: 10.1097/ICO.0b013e31823f0a64
Basic Investigation

Effects of Topical Human Amniotic Fluid and Human Serum in a Mouse Model of Keratoconjunctivitis Sicca

Quinto, Guilherme G. MD*,†; Camacho, Walter MD*; Castro-Combs, Juan MD*; Li, Li MD*; Martins, Suy Anne R. MD, PhD*; Wittmann, Priscila MD*; Campos, Mauro MD, PhD; Behrens, Ashley MD*

Collapse Box

Abstract

Purpose: To compare the effects of topical human amniotic fluid (HAF), topical human serum (HS), and topical artificial tears in a mouse model of dry eye.

Methods: Thirty C57BL/6 mice were divided into 3 treatment groups: HAF, HS, and preservative-free artificial tears. Dry eye was induced by an injection of botulinum toxin B (BTX-B) into the lacrimal gland. Tear production and ocular surface fluorescein staining were evaluated in each mouse at 6 time points during a 4-week period. Goblet cell density was assessed in stained histological sections. Apoptotic keratocytes were evaluated by terminal deoxynucleotidyl transferase–mediated dUTP nick-end labeling test assay.

Results: A significant decrease in tear production was observed 3 days after BTX-B injection in all groups. At week 1, the HAF and HS groups had improved tear production compared with the control group (P < 0.001 and P = 0.003, respectively). HAF had a significantly improved fluorescein staining score compared with the HS (P = 0.043) and control (P = 0.007) groups at week 2. Goblet cell density was significantly decreased in the control group compared with the HAF and HS groups (P < 0.001). No difference in the amount of terminal deoxynucleotidyl transferase–mediated dUTP nick-end labeling-positive keratocytes was observed among the groups.

Conclusion: HAF was superior to HS and artificial tears for improving corneal staining within 2 weeks of therapy in this induced mouse model of keratoconjunctivitis sicca. Clinical studies are needed to ascertain the benefits of these therapies in patients with ocular surface disorders associated with dry eye.

© 2012 Lippincott Williams & Wilkins, Inc.

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.